Kevin Gray, MD
Internal Medicine · Jackson, TNNPI 1952528077
Payments from drug & device makers
Across 573 payments — averaging $12.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$896
- Amgen$717
- Lilly USA, LLC$610
- Gilead$313
- Boehringer Ingelheim$274
- plus $2K from 23 others
What the payments were for
- Food & beverage$7,249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 242 | $2,460 |
| AbbVie(2 entities) | 90 | $896 |
| Amgen | 41 | $717 |
| Lilly USA, LLC | 46 | $610 |
| Gilead | 17 | $313 |
| Boehringer Ingelheim | 21 | $274 |
| Kowa Pharmaceuticals America, Inc. | 13 | $273 |
| AstraZeneca(2 entities) | 14 | $239 |
| Pfizer | 12 | $216 |
| GSK | 12 | $196 |
| Sanofi-aventis U.S. LLC | 13 | $183 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $115 |
| Abbott | 5 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $96 |
| Exact Sciences | 5 | $84 |
| Merck | 5 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Astellas Pharma US Inc | 3 | $60 |
| Novartis | 4 | $56 |
| Amarin Pharma, Inc. | 3 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Bayer | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$7,249 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $144,704 |
| EliquisApixaban | 99 | $58,652 |
| JanuviaSitagliptin Phosphate | 47 | $38,578 |
| JardianceEmpagliflozin | 19 | $29,920 |
| RybelsusSemaglutide | 23 | $28,449 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $25,371 |
| FarxigaDapagliflozin Propanediol | 62 | $24,870 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $18,230 |
| LinzessLinaclotide | 25 | $16,711 |
| Victoza 3-PakLiraglutide | 17 | $13,359 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $10,905 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,679 |
| Victoza 2-PakLiraglutide | 18 | $10,197 |
| XareltoRivaroxaban | 16 | $8,686 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Levemir | $2,460 | $175,522178 claims |
| PfizerEliquis | $216 | $58,65299 claims |
| MerckJanuvia, Janumet | $69 | $49,48462 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $196 | $39,43273 claims |
| Boehringer IngelheimJardiance | $274 | $29,92019 claims |
| AstraZenecaFarxiga | $239 | $24,87062 claims |
| AbbVieLinzess, Synthroid | $896 | $18,78159 claims |
| Johnson & JohnsonXarelto | $18 | $8,68616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Jackson
- Tracie WalkerJackson$488K
- Stephen BergquistJackson$25K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.